Kirn D - Search Results

1

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Kirn D, Martuza RL, Zwiebel J. Kirn D, et al. Nat Med. 2001 Jul;7(7):781-7. doi: 10.1038/89901. Nat Med. 2001. PMID: 11433341 Review.

2

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. Heise C, et al. Among authors: kirn d. Nat Med. 2000 Oct;6(10):1134-9. doi: 10.1038/80474. Nat Med. 2000. PMID: 11017145

3

ONYX-015: clinical data are encouraging.

Kirn D, Hermiston T, McCormick F. Kirn D, et al. Nat Med. 1998 Dec;4(12):1341-2. doi: 10.1038/3902. Nat Med. 1998. PMID: 9846551 No abstract available.

4

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Halldén G. Wang Y, et al. Among authors: kirn d. Clin Cancer Res. 2005 Jan 1;11(1):351-60. Clin Cancer Res. 2005. PMID: 15671566

5

E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.

Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J, Brooks G, Lemoine N, Kirn D. Wang Y, et al. Among authors: kirn d. Nat Biotechnol. 2003 Nov;21(11):1328-35. doi: 10.1038/nbt887. Epub 2003 Oct 12. Nat Biotechnol. 2003. PMID: 14555956

6

Oncolytic biotherapy: a novel therapeutic plafform.

Hawkins LK, Lemoine NR, Kirn D. Hawkins LK, et al. Among authors: kirn d. Lancet Oncol. 2002 Jan;3(1):17-26. doi: 10.1016/s1470-2045(01)00618-0. Lancet Oncol. 2002. PMID: 11905600 Review.

7

The emerging fields of suicide gene therapy and virotherapy.

Kirn D, Niculescu-Duvaz I, Hallden G, Springer CJ. Kirn D, et al. Trends Mol Med. 2002;8(4 Suppl):S68-73. doi: 10.1016/s1471-4914(02)02318-3. Trends Mol Med. 2002. PMID: 11927291 Review.

8

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress.

Liu TC, Galanis E, Kirn D. Liu TC, et al. Among authors: kirn d. Nat Clin Pract Oncol. 2007 Feb;4(2):101-17. doi: 10.1038/ncponc0736. Nat Clin Pract Oncol. 2007. PMID: 17259931 Review.

9

Virotherapy for cancer: current status, hurdles, and future directions.

Kirn D. Kirn D. Cancer Gene Ther. 2002 Dec;9(12):959-60. doi: 10.1038/sj.cgt.7700554. Cancer Gene Ther. 2002. PMID: 12522434 No abstract available.

10

The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider.

Vile R, Ando D, Kirn D. Vile R, et al. Among authors: kirn d. Cancer Gene Ther. 2002 Dec;9(12):1062-7. doi: 10.1038/sj.cgt.7700548. Cancer Gene Ther. 2002. PMID: 12522445 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results